Multiple myeloma bone disease is characterized by the development of osteolytic bone lesions. Here, the authors demonstrate that the checkpoint inhibitor PD-1H functions as a potential MMP-13 receptor on osteoclasts, mediating MMP-13 induced cytoskeleton reorganization, fusogenesis and bone resorption and further regulating osteolytic lesions.
- Jing Fu
- Shirong Li
- Suzanne Lentzsch
